scout

Edward Kim, MD, Mount Sinai Medical Center

Articles by Edward Kim, MD, Mount Sinai Medical Center

Biomarkers to Guide HCC Treatment Decisions

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Second-Line Treatment Approaches for Advanced HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

HCC: IO in Liver Transplant Recipients

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

The LEGACY Study in HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Selecting First-Line Therapy for Advanced HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Adjuvant Treatment Advances in Operable HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy for HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Neoadjuvant Therapy to Downstage HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Advances in Locoregional Therapy for Early Stage HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Current Role of Locoregional Therapy for Early Stage HCC

ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.

Latest Updated Articles